Summit Therapeutics Data From The Phase III HARMONi Trial Of Ivonescimab | Sep 08, 2025

Описание: Summit Therapeutics Inc. (NASDAQ: SMMT) today announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona, Spain..



#earningscall #StockMarketNews

If you want us to remove your company's earnings call or any other conference call, please reach out to [email protected].